The aim of the study was to show a reduction in LDL cholesterol with the use of monoclonal antibody alirocumab as an adjunct therapy to statins in patients already receiving the maximum tolerated dose of statins. This study randomized 720 patients with hypercholesterolemia and high cardiovascular risk to alirocumab 75 mg subcutaneously every 2 weeks versus ezetimibe 10 mg. All patients were already receiving the maximum tolerated dose of statins. At 24 weeks, LDL cholesterol reduction was 50.6% versus 20.7% in the ezetimibe group (p <0.0001). Cardiovascular events were 4.8% for the alirocumab group versus 3.7% for the ezetimibe group (p = ns).
Christopher Paul Cannon
2014-08-31
Original title: Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study.
